Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy
Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy
复制标题
生物大分子/脂质杂化纳米颗粒用于索拉非尼的控制递送以靶向肝细胞癌治疗
DOI：
10.2217/nnm-2016-0402
复制
发表时间：
2017-04-01
期刊：
影响因子：
5.5
通讯作者：
Zhang, Na
中科院分区：
文献类型：
--
作者：
Zhang, Jing;Wang, Tianqi;Zhang, Na
目的：由多种材料组成的杂化物在肿瘤治疗（包括肝细胞癌）中具有高度通用性的药物递送。本研究以索拉非尼（SF）为载体，制备了透明质酸（HA）/脂质杂化纳米粒（HA/SF-cLNS）。材料和方法：体外测定确定HA/SF-cLNS释放行为、酶降解、摄取和细胞毒性。使用荷H22肝癌异种移植物小鼠模型来评估体内生物分布和治疗功效。结果：HA/SF-cLNS可被透明质酸酶分解，释放药物。体内显像结果显示HA/cLNS可增强肿瘤局部药物蓄积。同时，HA/SF-cLNS在体内外均表现出较好的抗肿瘤效果。结论：HA/SF-cLNS具有增强SF抗肿瘤作用的潜力。
Aim: Hybrids composed of various materials are highly versatile for drug delivery in tumor therapy including hepatocellular carcinoma. Herein, a sorafenib (SF)-loaded biomacromolecule hyaluronic acid (HA)/lipid hybrid nanoparticles (HA/SF-cLNS) were developed for targeting drug delivery. Materials & methods: In vitro assays determined HA/SF-cLNS release behavior, enzymatic degradation, uptake and cytotoxicity. H22-bearing liver cancer xenograft murine models were used to evaluate the biodistribution and therapeutic efficacy in vivo. Results: HA/SF-cLNS could be disassembled and drug was released in response to hyaluronidase. In vivo imaging results demonstrated HA/cLNS could enhance drug accumulation at tumor site. Meanwhile, HA/SF-cLNS exhibited improved antitumor efficacy in vitro and in vivo. Conclusion: HA/SF-cLNS demonstrated the potential to enhance antitumor efficacy of SF.